BRPI1010768C8 - composto de fórmula (i) - Google Patents

composto de fórmula (i)

Info

Publication number
BRPI1010768C8
BRPI1010768C8 BRPI1010768A BRPI1010768A BRPI1010768C8 BR PI1010768 C8 BRPI1010768 C8 BR PI1010768C8 BR PI1010768 A BRPI1010768 A BR PI1010768A BR PI1010768 A BRPI1010768 A BR PI1010768A BR PI1010768 C8 BRPI1010768 C8 BR PI1010768C8
Authority
BR
Brazil
Prior art keywords
group
compound
alkyl
hydroxyl
coor1
Prior art date
Application number
BRPI1010768A
Other languages
English (en)
Inventor
Brock Carsten
Scherrer Didier
Mahuteau Florence
Gadea Gilles
Tazi Jamal
Cahuzac Nathalie
Roux Pierre
Najman Romain
Original Assignee
Abivax
Centre Nat Rech Scient
Inst Curie
Soc Splicos
Univ Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP09162630A external-priority patent/EP2261214A1/en
Priority claimed from EP20090305540 external-priority patent/EP2266972A1/en
Application filed by Abivax, Centre Nat Rech Scient, Inst Curie, Soc Splicos, Univ Montpellier filed Critical Abivax
Priority to BR122019013686-6A priority Critical patent/BR122019013686B1/pt
Priority to BR122019013687A priority patent/BR122019013687B1/pt
Publication of BRPI1010768A2 publication Critical patent/BRPI1010768A2/pt
Publication of BRPI1010768A8 publication Critical patent/BRPI1010768A8/pt
Publication of BRPI1010768B1 publication Critical patent/BRPI1010768B1/pt
Publication of BRPI1010768B8 publication Critical patent/BRPI1010768B8/pt
Publication of BRPI1010768C8 publication Critical patent/BRPI1010768C8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60—N-oxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)

Abstract

composto, e, composição farmacêutica a presente invenção diz respeito a composto (i) em que: significa um grupo piridazina, pirimidina ou pirazina, r independentemente representa um átomo de hidrogênio, um átomo de halogênio ou um grupo escolhido entre um grupo -cn, um grupo hidroxila, um grupo -coor1, um grupo fluoralquila (c1-c3), um grupo fluoralcóxi (c1-c3), um grupo -n02, um grupo -nr1r2, um grupo alcóxi (c1-c4), um grupo fenóxi e um grupo alquila (c1-c3), o dito alquila sendo opcionalmente mono-substituído por um grupo hidroxila, n é 1, 2 ou 3, n' é 1 ou 2, r' é um átomo de hidrogênio, um átomo de halogênio ou um grupo escolhido entre um grupo alquila (c1-c3), um grupo hidroxila, um grupo -coor1, um grupo -n02, um grupo -nr1r2, um morfolinila ou um grupo morfolino, um grupo n-metilpiperazinila, um grupo fluoralquila (c1-c3), um grupo alcóxi (c1-c4) e um grupo -cn, z é n ou c, y é n ou c, x é n ou c, w é n ou c, t é n ou c, u é n ou c, para uso como um agente para prevenir, inibir ou tratar câncer. alguns dos ditos compostos são inéditos e também formam parte da invenção.
BRPI1010768A 2009-06-12 2010-06-14 composto de fórmula (i) BRPI1010768C8 (pt)

Priority Applications (2)

Application Number Priority Date Filing Date Title
BR122019013686-6A BR122019013686B1 (pt) 2009-06-12 2010-06-14 Composto de fórmula (i), composto de fórmula (iq) e composição farmacêutica
BR122019013687A BR122019013687B1 (pt) 2009-06-12 2010-06-14 composto de fórmula (i)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US18654409P 2009-06-12 2009-06-12
US18655209P 2009-06-12 2009-06-12
EP09305540.8 2009-06-12
EP09162630A EP2261214A1 (en) 2009-06-12 2009-06-12 Compounds useful to treat premature aging and in particular progeria
US61/186,544 2009-06-12
US61/186,552 2009-06-12
EP09162630.9 2009-06-12
EP20090305540 EP2266972A1 (en) 2009-06-12 2009-06-12 New chemical molecules that inhibit the splicing mechanism for treating diseases resulting from splicing anomalies
PCT/IB2010/052650 WO2010143168A2 (en) 2009-06-12 2010-06-14 Compounds useful for treating cancer

Publications (5)

Publication Number Publication Date
BRPI1010768A2 BRPI1010768A2 (pt) 2016-11-01
BRPI1010768A8 BRPI1010768A8 (pt) 2019-07-30
BRPI1010768B1 BRPI1010768B1 (pt) 2019-10-22
BRPI1010768B8 BRPI1010768B8 (pt) 2020-03-10
BRPI1010768C8 true BRPI1010768C8 (pt) 2020-04-07

Family

ID=43309298

Family Applications (5)

Application Number Title Priority Date Filing Date
BRPI1010772A BRPI1010772B8 (pt) 2009-06-12 2010-06-14 compostos de quinolina, suas composições farmacêuticas e seus usos para tratar aids
BR122019013686-6A BR122019013686B1 (pt) 2009-06-12 2010-06-14 Composto de fórmula (i), composto de fórmula (iq) e composição farmacêutica
BRPI1010768A BRPI1010768C8 (pt) 2009-06-12 2010-06-14 composto de fórmula (i)
BR122019013687A BR122019013687B1 (pt) 2009-06-12 2010-06-14 composto de fórmula (i)
BRPI1012892A BRPI1012892B8 (pt) 2009-06-12 2010-06-14 compostos de fórmula (i), como tal, composição farmacêutica que os compreende e seu uso no tratamento de hgps, progeria, desordem de charcot-marie-tooth, síndrome de werner, diabetes, osteoporose e envelhecimento da pele

Family Applications Before (2)

Application Number Title Priority Date Filing Date
BRPI1010772A BRPI1010772B8 (pt) 2009-06-12 2010-06-14 compostos de quinolina, suas composições farmacêuticas e seus usos para tratar aids
BR122019013686-6A BR122019013686B1 (pt) 2009-06-12 2010-06-14 Composto de fórmula (i), composto de fórmula (iq) e composição farmacêutica

Family Applications After (2)

Application Number Title Priority Date Filing Date
BR122019013687A BR122019013687B1 (pt) 2009-06-12 2010-06-14 composto de fórmula (i)
BRPI1012892A BRPI1012892B8 (pt) 2009-06-12 2010-06-14 compostos de fórmula (i), como tal, composição farmacêutica que os compreende e seu uso no tratamento de hgps, progeria, desordem de charcot-marie-tooth, síndrome de werner, diabetes, osteoporose e envelhecimento da pele

Country Status (23)

Country Link
US (7) US20120277230A1 (pt)
EP (6) EP2440547B1 (pt)
JP (8) JP5826745B2 (pt)
KR (14) KR20120051643A (pt)
CN (13) CN104844570B (pt)
AU (3) AU2010258294B2 (pt)
BR (5) BRPI1010772B8 (pt)
CA (5) CA2764027C (pt)
CU (4) CU24461B1 (pt)
DK (4) DK2440547T3 (pt)
ES (4) ES2938532T3 (pt)
FI (3) FI2440546T3 (pt)
HR (3) HRP20230143T1 (pt)
HU (2) HUE061262T2 (pt)
LT (1) LT2440547T (pt)
MX (10) MX364280B (pt)
PL (4) PL2440545T3 (pt)
PT (4) PT3517534T (pt)
RU (1) RU2567752C2 (pt)
SI (1) SI2440547T1 (pt)
TR (1) TR201910781T4 (pt)
WO (3) WO2010143168A2 (pt)
ZA (2) ZA201109031B (pt)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20191460T1 (hr) * 2009-06-12 2019-11-15 Abivax Spojevi korisni za liječenje raka
SI2440547T1 (sl) * 2009-06-12 2023-05-31 Abivax Nove kemične molekule, ki zavirajo mehanizem spajanja za zdravljenje bolezni, ki so posledica napak pri spajanju
US10253020B2 (en) 2009-06-12 2019-04-09 Abivax Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging
AU2010289397B2 (en) 2009-09-03 2016-05-26 Bioenergenix Heterocyclic compounds for the inhibition of PASK
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
EP2465502A1 (en) * 2010-12-15 2012-06-20 Société Splicos Compounds useful for treating AIDS
WO2012094462A2 (en) 2011-01-05 2012-07-12 Bioenergenix Heterocyclic compounds for the inhibition of pask
WO2012119046A2 (en) 2011-03-02 2012-09-07 Bioenergenix Heterocyclic compounds for the inhibition of pask
US8916561B2 (en) 2011-03-02 2014-12-23 Bioenergenix, Llc Substituted quinoxaline compounds for the inhibition of PASK
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) * 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
FR2987627B1 (fr) 2012-03-05 2016-03-18 Splicos Utilisation de rbm39 comme biomarqueur
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
WO2013192423A2 (en) 2012-06-20 2013-12-27 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
US9145411B2 (en) 2012-08-02 2015-09-29 Asana Biosciences, Llc Substituted amino-pyrimidine derivatives
EP2882722B1 (en) 2012-08-13 2016-07-27 Takeda Pharmaceutical Company Limited Quinoxaline derivatives as gpr6 modulators
WO2014065209A1 (ja) * 2012-10-23 2014-05-01 日本曹達株式会社 ピリジン化合物またはその塩、有害生物防除剤、殺虫剤または殺ダニ剤、および外部寄生虫防除剤
US20160038503A1 (en) 2012-11-21 2016-02-11 David Richard Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives
GB201301571D0 (en) * 2012-11-27 2013-03-13 Fundanci N Pedro Barri De La Maza Product and use
US20140194465A1 (en) * 2013-01-04 2014-07-10 Novarx Corporation Compositions for treatment of cancer
EP2757161A1 (en) * 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
CN105530938B (zh) * 2013-07-05 2019-10-22 Abivax公司 用于治疗由逆转录病毒引起的疾病的化合物
US9879014B2 (en) 2013-07-12 2018-01-30 Kyoto University Method for screening substance capable of inhibiting abnormal splicing causative of onset or progress of disease
US10732182B2 (en) 2013-08-01 2020-08-04 Eutropics Pharmaceuticals, Inc. Method for predicting cancer sensitivity
JP6538044B2 (ja) 2013-10-30 2019-07-03 ユートロピクス ファーマシューティカルズ， インコーポレイテッド 化学療法感受性および化学毒性を判定する方法
JO3466B1 (ar) 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
WO2015123505A1 (en) 2014-02-14 2015-08-20 Takeda Pharmaceutical Company Limited Pyridopyrazines modulators of gpr6
RU2715236C2 (ru) 2014-03-26 2020-02-26 Астекс Терапьютикс Лтд Комбинации
HRP20210319T1 (hr) 2014-03-26 2021-04-30 Astex Therapeutics Ltd. Kombinacije inhibitora fgfr i inhibitora igf1r
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
EP2974729A1 (en) * 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
EP2975034A1 (en) 2014-07-17 2016-01-20 Abivax A quinoline derivative for the treatment of inflammatory diseases and AIDS
WO2016120495A1 (en) 2015-01-30 2016-08-04 Centre National De La Recherche Scientifique (Cnrs) Delta133p53beta and delta133p53gamma isoforms are biomarkers of cancer stem cells
TWI719960B (zh) 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
EP3059236A1 (en) 2015-02-23 2016-08-24 Abivax A new quinoline derivative for use in the treatment and prevention of viral infections
EP3058940A1 (en) * 2015-02-23 2016-08-24 Abivax Quinoline derivatives for use in the treatment or prevention of viral infection
EP3059591A1 (en) * 2015-02-23 2016-08-24 Abivax Methods for screening compounds for treating or preventing a viral infection or a virus-related condition
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
US11155555B2 (en) 2015-09-23 2021-10-26 Janssen Pharmaceutica Nv Compounds
EP3353164B1 (en) 2015-09-23 2021-11-03 Janssen Pharmaceutica, N.V. Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
AU2016371466B2 (en) 2015-12-17 2020-04-09 Alonbio Ltd Small Molecules for Inhibiting Chemokine Activity and/or Cancer Cells Growth
EP3390378B1 (en) 2015-12-17 2022-03-30 AlonBio Ltd. Small molecules against cancer
EA035621B1 (ru) * 2016-02-03 2020-07-16 Янссен Фармацевтика Нв Лиганды для pet-визуализации тау-белков
PT3429998T (pt) 2016-03-18 2021-11-04 Prosynergia S A R L Processo para preparação de derivados de quinolin-2-il-fenilamina e seus sais
US11168068B2 (en) 2016-07-18 2021-11-09 Janssen Pharmaceutica Nv Tau PET imaging ligands
AR112027A1 (es) * 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol
WO2019002228A1 (en) 2017-06-26 2019-01-03 Institut Pasteur TREATMENTS TO REMOVE HIV RESERVOIRS AND REDUCE VIRAL LOAD
US10889566B2 (en) * 2017-08-29 2021-01-12 Chulabhorn Foundation Derivatives and composition of quinoline and naphthyridine
US12528810B2 (en) * 2018-03-01 2026-01-20 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK/CLK and uses thereof
WO2019186277A1 (en) 2018-03-28 2019-10-03 Institut Pasteur Ultrasensitive hiv-1 p24 detection assay
EP3594205A1 (en) * 2018-07-09 2020-01-15 Abivax Phenyl-n-aryl derivatives for treating a rna virus infection
EP3594206A1 (en) 2018-07-09 2020-01-15 Abivax Phenyl-n-quinoline derivatives for treating a rna virus infection
EP3669873A1 (en) 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use ine the traeatment of inflammation diseases
WO2020128033A1 (en) 2018-12-20 2020-06-25 Institut Pasteur Cellular metabolism of hiv-1 reservoir seeding in cd4+ t cells
EP3669874A1 (en) * 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use in the treatment or prevention of cancer
ES3014809T3 (en) 2019-05-15 2025-04-25 Alonbio Ltd Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death
EP3858815A1 (en) 2020-01-31 2021-08-04 Abivax Co-crystals and salts of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine
JP7762386B2 (ja) * 2020-01-31 2025-10-30 アビバックス ８－クロロ－ｎ－（４－（トリフルオロメトキシ）フェニル）キノリン－２－アミンの非晶質固体分散物
EP3858336A1 (en) 2020-01-31 2021-08-04 Abivax Amorphous solid dispersion of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine
CA3172179A1 (en) 2020-03-20 2021-09-23 Jamal Tazi Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
CR20230057A (es) 2020-07-02 2023-08-15 Incyte Corp Compuestos tríciclicos de urea como inhibidores de jak2 v617f
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
AR125273A1 (es) 2021-02-25 2023-07-05 Incyte Corp Lactamas espirocíclicas como inhibidores de jak2 v617f
EP4063351A1 (en) 2021-03-26 2022-09-28 Abivax Preparation method of quinoline derivative compounds
TW202313592A (zh) 2021-05-27 2023-04-01 大陸商江蘇恆瑞醫藥股份有限公司 喹啉胺類化合物、其製備方法及其在醫藥上的應用
KR20230072900A (ko) 2021-11-18 2023-05-25 동우 화인켐 주식회사 마이크로 led 구조체 및 이의 제조방법
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator
EP4215196A1 (en) 2022-01-24 2023-07-26 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a jak inhibitor
WO2023138657A1 (zh) * 2022-01-24 2023-07-27 江苏恒瑞医药股份有限公司 喹啉胺类化合物、其制备方法及其在医药上的应用
AU2023235313A1 (en) 2022-03-17 2024-10-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
CN118027024A (zh) * 2022-11-14 2024-05-14 南京同诺康医药科技有限公司 吡啶并[1,2-a]嘧啶-4-酮衍生物及其制备方法和用途
CN120152971A (zh) 2022-11-25 2025-06-13 江苏恒瑞医药股份有限公司 一种喹啉胺类化合物晶型及其制备方法
WO2025027388A1 (en) 2023-08-01 2025-02-06 Abivax Obefazimod for treatment of ulcerative colitis
CN121532389A (zh) * 2023-08-30 2026-02-13 江苏正大丰海制药有限公司 用于调节微小rna-124活性的化合物

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR400973A (fr) 1909-03-19 1909-08-13 Jean Victor Massillon Nouveau sertisseur à main pour la fabrication des cartouches
GB585362A (en) 1944-08-31 1947-02-05 Francis Henry Swinden Curd New heterocyclic compounds
BE486034A (pt) 1947-11-28
DE958647C (de) 1952-12-28 1957-02-21 Hoechst Ag Verfahren zur Herstellung von 7-Amino-2-oxy-4-methyl-chinolinen
FR2387229A1 (fr) 1977-04-13 1978-11-10 Anvar Dipyrido (4,3-b) (3,4-f) indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant
FR2436786A1 (fr) 1978-09-21 1980-04-18 Anvar Nouveaux derives des pyrido (4,3-b) carbazoles (ellipticines), substitues en position 1 par une chaine polyaminee, leur obtention et leur application a titre de medicaments
FR2627493B1 (fr) 1988-02-23 1991-10-31 Sanofi Sa Procede de preparation de derives d'isoquinoleine
FR2645861A1 (fr) 1989-04-17 1990-10-19 Inst Nat Sante Rech Med Utilisation de dipyrido (4,3-b) (3,4-f) indoles pour la preparation de medicaments utiles pour le traitement du sida
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
CA2368688C (en) 1999-04-05 2009-08-11 City Of Hope Novel inhibitors of formation of advanced glycation endproducts (age's)
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
DE10013318A1 (de) * 2000-03-17 2001-09-20 Merck Patent Gmbh Formulierung enthaltend Chinoxalinderivate
KR100856622B1 (ko) 2001-01-22 2008-09-03 메모리 파마슈티칼스 코포레이션 포스포디에스테라제 4 억제제
MXPA04011472A (es) 2002-05-22 2005-02-14 Amgen Inc Derivados de amino-piridina, piridina y piridazina para usarse como ligandos del receptor vaniloide para el tratamiento del dolor.
AU2002950217A0 (en) 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
AU2003256616B2 (en) * 2002-07-19 2009-08-27 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs
FR2849474B3 (fr) 2002-12-27 2004-12-03 Olivier Jean Noel Juin Installation de transformation de l'energie cinetique d'un fluide en energie electrique
WO2004078731A1 (en) 2003-03-06 2004-09-16 'chemical Diversity Research Institute', Ltd. Quinoline-carboxylic acids and the derivatives thereof, a focused library
CA2518398A1 (en) * 2003-03-10 2004-09-23 Schering Corporation Heterocyclic kinase inhibitors: methods of use and synthesis
FR2859475A1 (fr) 2003-09-04 2005-03-11 Centre Nat Rech Scient Utilisation de composes derives d'ellipticine et d'aza-ellipticine pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage
FR2859474B1 (fr) 2003-09-04 2006-01-13 Centre Nat Rech Scient Utilisation de composes derives d'indole pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage
US7691866B2 (en) * 2003-10-16 2010-04-06 Novartis Vaccines And Diagnostics, Inc. 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of Raf kinase
CN1905873A (zh) * 2003-11-19 2007-01-31 阵列生物制药公司 Mek的杂环抑制剂及其使用方法
WO2006051311A1 (en) * 2004-11-12 2006-05-18 Galapagos Nv Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
EP1853265B1 (en) 2005-01-28 2016-01-27 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Farnesyltransferase inhibitors for use in the treatment of laminopathies, cellular aging and atherosclerosis
US20090088513A1 (en) * 2005-06-29 2009-04-02 Adeka Corporation Resin additive composition and resin composition
FR2903312B1 (fr) 2006-07-05 2008-09-26 Univ Aix Marseille Ii Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
WO2008008234A1 (en) * 2006-07-07 2008-01-17 Targegen, Inc. 2-amino-5-substituted pyrimidine inhibitors
KR20090111847A (ko) * 2007-01-19 2009-10-27 아디아 바이오사이언스즈 인크. Ｍｅｋ 억제제
FR2912745A1 (fr) 2007-02-19 2008-08-22 Centre Nat Rech Scient Nouveaux composes derives d'indole et compositions pharmaceutiques les contenant
WO2008115870A2 (en) * 2007-03-16 2008-09-25 Mount Sinai School Of Medicine Induction and/or maintenance of tumor dormancy by disruption of urokinase plasminogen activator receptor-integrin interaction
CN101679150B (zh) * 2007-05-17 2013-05-15 Lg化学株式会社 蒽衍生物和使用该蒽衍生物的有机电子器件
UY31272A1 (es) * 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
CN101801194A (zh) 2007-08-15 2010-08-11 记忆医药公司 具有5-ht6受体亲和力的3’取代的化合物
WO2009029617A1 (en) * 2007-08-27 2009-03-05 Kalypsys, Inc. Diarylamine-substituted quinolones useful as inducible nitric oxide synthase inhibitors
KR100974562B1 (ko) * 2007-12-31 2010-08-06 다우어드밴스드디스플레이머티리얼 유한회사 신규한 유기 발광 화합물 및 이를 발광재료로서 채용하고있는 유기 발광 소자
FR2926297B1 (fr) 2008-01-10 2013-03-08 Centre Nat Rech Scient Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage.
EP2384337A1 (en) * 2009-01-05 2011-11-09 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Means and method for the treatment of antibody deficiency diseases based on il-21 and il-21 variants
BRPI1007222A2 (pt) * 2009-01-06 2016-02-23 Inserm Inst Nat De La Santé Et De La Rech Médicale agente de depleção de células b para tratamento de aterosclerose
JP2012514585A (ja) * 2009-01-06 2012-06-28 ディーエスエム アイピー アセッツ ビー．ブイ． レスベラトロール中間体に対する方法
SI2440547T1 (sl) 2009-06-12 2023-05-31 Abivax Nove kemične molekule, ki zavirajo mehanizem spajanja za zdravljenje bolezni, ki so posledica napak pri spajanju
HRP20191460T1 (hr) * 2009-06-12 2019-11-15 Abivax Spojevi korisni za liječenje raka
EP2266972A1 (en) 2009-06-12 2010-12-29 Splicos New chemical molecules that inhibit the splicing mechanism for treating diseases resulting from splicing anomalies
US8962583B2 (en) 2009-06-25 2015-02-24 The Brigham And Women's Hospital, Inc. Treatment of inflammatory diseases using miR-124
EP2465502A1 (en) 2010-12-15 2012-06-20 Société Splicos Compounds useful for treating AIDS
WO2014055944A1 (en) 2012-10-04 2014-04-10 Oyagen, Inc. Small molecules as anti-hiv agents that disrupt vif self-association and methods of use thereof
EP2757161A1 (en) 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
JP2015120566A (ja) * 2013-12-20 2015-07-02 ニチユ三菱フォークリフト株式会社 荷役車両

Also Published As

Publication number Publication date
US20150299129A1 (en) 2015-10-22
KR101897221B1 (ko) 2018-09-10
KR20180100736A (ko) 2018-09-11
US20150307478A1 (en) 2015-10-29
EP2440547B1 (en) 2022-11-30
MX340095B (es) 2016-06-27
EP2440545B1 (en) 2019-04-24
KR101973348B1 (ko) 2019-04-26
MX364282B (es) 2019-04-22
BRPI1010768B1 (pt) 2019-10-22
KR101982462B1 (ko) 2019-05-24
JP2012529494A (ja) 2012-11-22
WO2010143170A3 (en) 2011-08-11
US10017498B2 (en) 2018-07-10
MX364280B (es) 2019-04-22
DK2440547T3 (da) 2023-02-20
JP2015155453A (ja) 2015-08-27
KR102016891B1 (ko) 2019-08-30
KR101863021B1 (ko) 2018-05-30
HUE061262T2 (hu) 2023-05-28
DK3517534T3 (da) 2024-05-27
FI2440547T3 (fi) 2023-03-14
CN106928194A (zh) 2017-07-07
KR20190018569A (ko) 2019-02-22
BRPI1010772A2 (pt) 2016-11-01
JP7042245B2 (ja) 2022-03-25
KR20190018567A (ko) 2019-02-22
CN104844510A (zh) 2015-08-19
CA2764026A1 (en) 2010-12-16
CA2764027A1 (en) 2010-12-16
HK1173447A1 (zh) 2013-05-16
KR20190018570A (ko) 2019-02-22
MX2011013120A (es) 2012-07-23
MX353776B (es) 2018-01-29
EP2440546A2 (en) 2012-04-18
CN109776496B (zh) 2021-09-28
CN104844510B (zh) 2019-04-23
CU20150024A7 (es) 2015-09-29
CN104945379B (zh) 2018-11-30
CU20110229A7 (es) 2012-06-21
ES2938532T3 (es) 2023-04-12
CU20110228A7 (es) 2012-04-15
CU24124B1 (es) 2015-08-27
BRPI1010768A8 (pt) 2019-07-30
BRPI1010768B8 (pt) 2020-03-10
CN109776496A (zh) 2019-05-21
CN102596935B (zh) 2015-02-18
DK2440545T3 (da) 2019-07-22
KR20180101727A (ko) 2018-09-13
MX359575B (es) 2018-10-03
BRPI1012892A2 (pt) 2018-03-13
JP5905385B2 (ja) 2016-04-20
CA2965791A1 (en) 2010-12-16
CN102574835B (zh) 2014-04-16
PL2440545T3 (pl) 2019-11-29
US20120329796A1 (en) 2012-12-27
US9145367B2 (en) 2015-09-29
CU24461B1 (es) 2020-01-03
KR102016889B1 (ko) 2019-08-30
CN104844570B (zh) 2018-11-02
CU20110230A7 (es) 2012-04-15
CN106905232B (zh) 2019-09-27
KR20190018568A (ko) 2019-02-22
ES2940885T3 (es) 2023-05-12
MX367601B (es) 2019-08-28
KR101982463B1 (ko) 2019-05-24
PT2440547T (pt) 2023-02-17
CN104945378B (zh) 2018-11-20
CA3070823C (en) 2021-09-21
EP3521283B1 (en) 2024-02-28
US20140080831A1 (en) 2014-03-20
KR20120049860A (ko) 2012-05-17
LT2440547T (lt) 2023-03-10
AU2010258295A1 (en) 2012-01-19
FI2440546T3 (fi) 2023-03-30
HK1200363A1 (en) 2015-08-07
DK2440546T3 (da) 2023-03-27
JP2015187151A (ja) 2015-10-29
EP2440546B1 (en) 2022-12-28
HRP20240582T1 (hr) 2024-07-19
JP2012529493A (ja) 2012-11-22
KR20180100737A (ko) 2018-09-11
CN106928205B (zh) 2019-09-24
KR20170124646A (ko) 2017-11-10
HRP20230248T1 (hr) 2023-04-14
CN104945379A (zh) 2015-09-30
KR101769616B1 (ko) 2017-08-18
BRPI1012892B1 (pt) 2020-10-27
RU2567752C2 (ru) 2015-11-10
PT2440545T (pt) 2019-07-19
PL2440547T3 (pl) 2023-09-11
WO2010143170A2 (en) 2010-12-16
KR20120051643A (ko) 2012-05-22
CN102596935A (zh) 2012-07-18
AU2010258294A1 (en) 2012-01-19
AU2010258294B2 (en) 2015-07-30
CU24093B1 (es) 2015-04-29
HUE045548T2 (hu) 2019-12-30
EP3517534A1 (en) 2019-07-31
KR101982461B1 (ko) 2019-05-24
HK1173726A1 (zh) 2013-05-24
CN102625804A (zh) 2012-08-01
MX364279B (es) 2019-04-22
BR122019013687B1 (pt) 2020-04-14
EP4198022A1 (en) 2023-06-21
JP5826745B2 (ja) 2015-12-02
CA2965791C (en) 2020-06-09
US20120277230A1 (en) 2012-11-01
KR102016893B1 (ko) 2019-08-30
CN102574835A (zh) 2012-07-11
CN104844570A (zh) 2015-08-19
ES2985082T3 (es) 2024-11-04
AU2010258214A1 (en) 2012-01-19
JP6158250B2 (ja) 2017-07-05
CN102625804B (zh) 2015-04-08
KR20190018571A (ko) 2019-02-22
RU2011149572A (ru) 2013-07-20
CA2764027C (en) 2020-11-03
CN106928194B (zh) 2019-11-12
FI3517534T3 (fi) 2024-05-16
PT3517534T (pt) 2024-05-17
KR101789275B1 (ko) 2017-11-20
JP6158251B2 (ja) 2017-07-05
HK1212990A1 (zh) 2016-06-24
EP2440545A2 (en) 2012-04-18
MX2011013122A (es) 2012-07-23
EP2440547A2 (en) 2012-04-18
AU2010258214B2 (en) 2015-08-20
PT2440546T (pt) 2023-03-27
HRP20230143T1 (hr) 2023-03-31
JP2020045342A (ja) 2020-03-26
CA2764024A1 (en) 2010-12-16
ZA201109031B (en) 2013-02-27
CA3070823A1 (en) 2010-12-16
EP3521283A1 (en) 2019-08-07
JP2015187150A (ja) 2015-10-29
MX373120B (es) 2020-04-30
HK1212702A1 (zh) 2016-06-17
JP2015187152A (ja) 2015-10-29
BRPI1010772B1 (pt) 2020-10-27
CA2764024C (en) 2017-12-05
US20120283265A1 (en) 2012-11-08
CN113004249A (zh) 2021-06-22
WO2010143168A3 (en) 2011-06-09
CN106928205A (zh) 2017-07-07
TR201910781T4 (tr) 2019-08-21
PL3517534T3 (pl) 2024-06-24
BRPI1010772B8 (pt) 2021-05-25
JP6041671B2 (ja) 2016-12-14
AU2010258295B2 (en) 2015-09-03
KR20170092720A (ko) 2017-08-11
CN104945378A (zh) 2015-09-30
CN103948594A (zh) 2014-07-30
RU2011149571A (ru) 2013-07-20
MX364989B (es) 2019-05-17
HK1173153A1 (en) 2013-05-10
WO2010143169A3 (en) 2011-11-10
MX338823B (es) 2016-05-03
MX2011013119A (es) 2012-07-04
KR102016890B1 (ko) 2019-08-30
US9908869B2 (en) 2018-03-06
KR102016892B1 (ko) 2019-08-30
BR122019013686B1 (pt) 2020-03-17
ES2736198T3 (es) 2019-12-26
CN106905232A (zh) 2017-06-30
BRPI1012892B8 (pt) 2021-05-25
KR20120054585A (ko) 2012-05-30
KR20180100735A (ko) 2018-09-11
HK1213246A1 (zh) 2016-06-30
US9637475B2 (en) 2017-05-02
PL2440546T3 (pl) 2023-07-10
CU24245B1 (es) 2017-02-02
US20140288120A1 (en) 2014-09-25
EP3517534B1 (en) 2024-02-28
WO2010143168A2 (en) 2010-12-16
WO2010143169A2 (en) 2010-12-16
SI2440547T1 (sl) 2023-05-31
HK1213247A1 (zh) 2016-06-30
US9108919B2 (en) 2015-08-18
ZA201109032B (en) 2013-02-27
CA2764026C (en) 2019-10-29
CN103948594B (zh) 2016-10-26
BRPI1010768A2 (pt) 2016-11-01
JP2012529495A (ja) 2012-11-22

Similar Documents

Publication Publication Date Title
BRPI1010768B8 (pt) composto de fórmula (i)
BR112016000127A8 (pt) compostos bicíclicos úteis para tratar doenças causadas por retrovírus
BR112013001632A2 (pt) composto, composição farmacêutica, método de inibir uma atividade uma jak quinase in vitro, uso de um composto, ou da composição farmacêutica, e, método de fabricar um composto
BR112015020650A2 (pt) inibidores de histona demetilases
BR112014014909A2 (pt) agonistas de tgr5 não sistêmicos
BR112012010186B8 (pt) derivados de heteroarila contendo n como inibidores de quinase jak3 e composição farmacêutica compreendendo os mesmos
UY33539A (es) Compuestos químicos alk
BR112015024530A8 (pt) compostos derivados de naftiridina úteis como antagonistas de integrina alfa-v-beta-6, composição farmacêutica, e, uso de um composto
BRPI1009637A2 (pt) composto, composição e uso de um composto
BRPI0813244B8 (pt) compostos derivados de pirazinona, composições compreendendo ditos compostos, uso dos compostos no tratamento de doenças de pulmão e composto intermediário
NO20081454L (no) Met-kinaseinhibitorer
EA201300211A1 (ru) N-ацилсульфонамидные промоторы апоптоза
BR112012032087A2 (pt) composto, medicamento, e, uso de um composto
PE20151981A1 (es) Pontenciador de inhibidores del homologo de zeste
BR112014000792A2 (pt) compostos de piperidinila para uso como inibidores da tanquirase
BR112013019643A2 (pt) inibidores de alk, uso e composição farmacêutica compreendendo os mesmos
BR112012021659A2 (pt) composto, composição farmacêutica, método para tratar e/ou prevenir distúrbios e doenças.
BRPI0807597B8 (pt) composição farmacêutica, e, uso de um derivado de pirazina ou um sal do mesmo e um ou mais inibidor(es) de neuraminidase em combinação
ECSP078062A (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
PE20151754A1 (es) Estra-1,3,5(10),16-tetraeno-3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3)
BRPI0506760A (pt) derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina como inibidores de igf-ir
BR112012024422A2 (pt) uso de novos inibidores pan-cdk para tratamento de tumores
BR112012027387A2 (pt) composição para controle de doenças de plantas e uso da mesma
BR112014031969A2 (pt) derivados de pirimidinona como agentes antimaláricos
BR112015020222A8 (pt) composto de azetidiniloxifenilpirrolidina, seus usos, e composições farmacêuticas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) , INSTITUT CURIE (FR) , UNIVERSITE MONTPELLIER 2 (FR) , ABIVAX (FR)

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/06/2010, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 2546 DE 22/10/2019,QUANTO AO ITEM (30) PRIORDADE UNIONISTA.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2566 DE 10/03/2020 QUANTO A PRIORIDADE UNIONISTA.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.